Oesophageal Cancer Trial, Recruiting NCT06189898 Sponsor: Sebastian Zschaeck Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT06189898
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with a specific type of esophageal cancer (squamous cell, undifferentiated, or adenocarcinoma) at a mid-to-advanced stage (UICC stage II to IVA, up to a certain tumor size called T4a).
  • People with a general health and activity level rated as reasonably functional (ECOG performance status 0–2, meaning able to carry out daily activities with little to moderate limitation).
  • People who have had a full set of staging tests completed, including a camera examination of the esophagus and stomach, an internal ultrasound scan, a CT scan of the neck, chest, and abdomen, and a breathing function test.
  • People whose blood counts, kidney, liver, and lung function results meet minimum required levels (confirm with trial site for exact values).
  • People who are willing and able to sign a written consent form agreeing to take part.
  • People who are capable of becoming pregnant and are willing to use effective contraception throughout the treatment period.

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body (known as distant metastases).
  • People who have previously received high-dose radiation treatment to the chest or abdomen.
  • People whose primary tumor has reached a more advanced local stage called cT4b, meaning it has grown into nearby structures in a way that makes it harder to treat.
  • People who have, or have had, another cancer that the treating doctor considers more likely to be life-threatening than the esophageal cancer being studied.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sebastian Zschaeck, MD, Charite University, Berlin, Germany

Phone: ++4930450650764

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Sebastian Zschaeck
Registry
ClinicalTrials.gov
Start date
15 December 2023
Est. completion
31 January 2029

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov